ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Quinidine

Also written as “AVP-786”, “Quinidine Sulfate” and “Quinidine sulfate tablets”.

Its studies are mostly in Psychomotor Agitation · Schizophrenia · Dementia · Disruptive, Impulse Control, and Conduct Disorders, led by 4 companies.

Drug pageQuinidine: every studyAll 23 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since May 11, 201517 company-led studies, 1 open or runningNext primary completion: Nov 30, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Otsukaits history only130 open or runningphase 3since May 11, 2015Jun 23, 2014none ahead
Boehringer Ingelheimits history only20 open or runningphase 1since Jun 20, 2014Jun 20, 2014none ahead
Bristol-Myers Squibbits history only10 open or runningphase 1since Jun 25, 2024Jun 25, 2024none ahead
Trevi Therapeutics11 open or runningphase 1since Nov 12, 2026Nov 12, 2026Nov 30, 2026phase 1 · NCT07946575

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Trevi Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 12, 2026First study: phase 1 study in Healthy ParticipantsFirst studyNCT07946575 · 30 planned · United States

Ahead

  1. Nov 30, 2026Primary completion: phase 1 study in Healthy ParticipantsNCT07946575

TargetBeta

“Sodium channel alpha subunit blocker; Sodium channel alpha subunit blocker”ChEMBL 37, by rule

Other programs on the same 10 targets

ProgramCompanyFurthest phaseStudies
LidocaineruleKeenova Therapeuticsphase 463
LamotrigineruleGlaxoSmithKlinephase 461
Carbamazepinerulegrin-therapeutics-incphase 421
DronedaroneruleSanofiphase 418
chloroprocainerulesintetica-saphase 48
RiluzoleruleSanofiphase 46
PrilocaineruleHaisco Pharmaceutical Groupphase 42
CarticaineruleLaboratoires Theaphase 41
Ropivacainerulepainreform-ltdphase 317
PhenytoinruleViatrisphase 310
rufinamideruleEisaiphase 37

Studies

The one study Trevi Therapeutics leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07946575Healthy Participants · United States1RecruitingNov 30, 202630

How it is read

Names in the registry

  • “AVP-786”, 13 entries
  • “Quinidine Sulfate”, 1 entry
  • “Quinidine”, 1 entry
  • “Quinidine sulfate tablets”, 1 entry
  • “quinidine”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.